BR112018074056A2 - composições e métodos relacionados a construtos de fc manipulados - Google Patents

composições e métodos relacionados a construtos de fc manipulados

Info

Publication number
BR112018074056A2
BR112018074056A2 BR112018074056-0A BR112018074056A BR112018074056A2 BR 112018074056 A2 BR112018074056 A2 BR 112018074056A2 BR 112018074056 A BR112018074056 A BR 112018074056A BR 112018074056 A2 BR112018074056 A2 BR 112018074056A2
Authority
BR
Brazil
Prior art keywords
constructs
manipulated
compositions
methods related
methods
Prior art date
Application number
BR112018074056-0A
Other languages
English (en)
Portuguese (pt)
Inventor
J. Bosques Carlos
C. Lansing Jonathan
Ortiz Daniel
Rutitzky Laura
J. Washburn Nathaniel
Original Assignee
Momenta Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals, Inc. filed Critical Momenta Pharmaceuticals, Inc.
Publication of BR112018074056A2 publication Critical patent/BR112018074056A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Prostheses (AREA)
BR112018074056-0A 2016-05-23 2017-05-23 composições e métodos relacionados a construtos de fc manipulados BR112018074056A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662340322P 2016-05-23 2016-05-23
US62/340,322 2016-05-23
US201762443451P 2017-01-06 2017-01-06
US62/443,451 2017-01-06
PCT/US2017/034084 WO2017205434A1 (en) 2016-05-23 2017-05-23 Compositions and methods related to engineered fc constructs

Publications (1)

Publication Number Publication Date
BR112018074056A2 true BR112018074056A2 (pt) 2019-03-06

Family

ID=60412547

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112018074056-0A BR112018074056A2 (pt) 2016-05-23 2017-05-23 composições e métodos relacionados a construtos de fc manipulados
BR112018074032-2A BR112018074032A2 (pt) 2016-05-23 2017-05-23 composições e métodos relacionados a construtos de fc manipulados

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112018074032-2A BR112018074032A2 (pt) 2016-05-23 2017-05-23 composições e métodos relacionados a construtos de fc manipulados

Country Status (15)

Country Link
US (4) US11155640B2 (enExample)
EP (2) EP3484514B1 (enExample)
JP (5) JP2019519527A (enExample)
KR (3) KR102635635B1 (enExample)
CN (4) CN109789203B (enExample)
AU (2) AU2017272111B2 (enExample)
BR (2) BR112018074056A2 (enExample)
CA (2) CA3025306A1 (enExample)
DK (1) DK3484514T3 (enExample)
ES (1) ES2973251T3 (enExample)
IL (3) IL263211B2 (enExample)
NZ (2) NZ749292A (enExample)
PL (1) PL3484514T3 (enExample)
SG (3) SG11201810466PA (enExample)
WO (2) WO2017205436A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106661125B (zh) 2014-05-02 2021-10-01 动量制药公司 涉及工程化Fc构建体的组合物和方法
US12391759B2 (en) 2016-03-02 2025-08-19 Momenta Pharmaceuticals, Inc. Methods related to engineered Fc constructs
KR102635635B1 (ko) * 2016-05-23 2024-02-14 모멘타 파머슈티컬스 인코포레이티드 유전자 조작 Fc 작제물에 관한 조성물 및 방법
CN110650748B (zh) 2017-01-06 2024-01-02 动量制药公司 与经工程改造的Fc构建体相关的组合物和方法
CN113164592A (zh) * 2018-07-11 2021-07-23 动量制药公司 与工程化Fc-抗原结合结构域构建体有关的组合物和方法
CA3106207A1 (en) * 2018-07-11 2020-01-16 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ctla-4
CN112996910A (zh) * 2018-07-11 2021-06-18 动量制药公司 与靶向PD-L1的工程化Fc-抗原结合结构域构建体有关的组合物和方法
CA3106254A1 (en) * 2018-07-11 2020-01-16 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs
US20250346676A1 (en) * 2018-07-11 2025-11-13 Momenta Pharmaceuticals, Inc. COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO CCR4
BR112021000392A2 (pt) * 2018-07-11 2021-04-06 Momenta Pharmaceuticals, Inc. Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulados
CA3106142A1 (en) * 2018-07-11 2020-01-16 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs targeted to cd38
BR112021000415A2 (pt) * 2018-07-11 2021-04-06 Momenta Pharmaceuticals, Inc. Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulados
KR102661494B1 (ko) 2019-03-08 2024-04-29 에이치엘만도 주식회사 랙구동형 동력 보조 조향장치
KR20220062084A (ko) 2019-09-13 2022-05-13 체에스엘 베링 렝나우 아게 면역 복합체 매개된 콩팥 장애의 치료를 위한 재조합 IgG Fc 다량체
JP2023505493A (ja) * 2019-12-06 2023-02-09 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト Ｆｃ多量体の安定組成物
CN111808170A (zh) * 2020-06-29 2020-10-23 江苏为真生物医药技术股份有限公司 多肽、hla-dr蛋白及其制备方法和应用
WO2022125355A1 (en) * 2020-12-07 2022-06-16 Invetx Inc. Compositions for increasing half-life of a therapeutic agent in livestock animals and methods of use
WO2024206820A1 (en) * 2023-03-30 2024-10-03 Dna Twopointo, Inc. Fc engineering for heterodimeric antibody format

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2556219B1 (fr) 1983-12-07 1987-06-26 Merieux Inst Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines
US5426641A (en) 1994-01-28 1995-06-20 Bell Communications Research, Inc. Adaptive class AB amplifier for TDMA wireless communications systems
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AU3804397A (en) 1996-06-14 1998-01-07 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
US20090074839A1 (en) 1997-01-22 2009-03-19 Marton Milankovits Pharmaceutical Compositions Primarily for the Treatment and Prevention of Genitourinary Infections and their Extragenital Complications
US7951917B1 (en) * 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2001045746A2 (en) 1999-12-24 2001-06-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
WO2008088422A2 (en) 2006-10-25 2008-07-24 Amgen Inc. Toxin peptide therapeutic agents
BRPI0620639A2 (pt) 2006-12-21 2011-11-22 Micromet Ag anticorpos de cadeia simples biespecìficos e composição farmacêutica compreendendo os mesmos
US20080260738A1 (en) 2007-04-18 2008-10-23 Moore Margaret D Single chain fc, methods of making and methods of treatment
BRPI0811857A2 (pt) 2007-05-14 2014-10-21 Biogen Idec Inc Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados.
EP2185589B1 (en) 2007-06-01 2016-01-06 University of Maryland, Baltimore Immunoglobulin constant region fc receptor binding agents
PT2235064E (pt) 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
SG189730A1 (en) 2008-04-02 2013-05-31 Macrogenics Inc Her2/neu-specific antibodies and methods of using same
WO2010042481A1 (en) 2008-10-06 2010-04-15 University Of Chicago Compositions and methods related to bacterial eap, emp, and/or adsa proteins
US20100143353A1 (en) 2008-12-04 2010-06-10 Mosser David M POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (lgG) AND METHODS OF USING THE SAME
CA2747011C (en) 2008-12-18 2018-06-19 Dana-Farber Cancer Institute, Inc. Nkg2d-fc for immunotherapy
AU2010206681A1 (en) 2009-01-23 2011-09-01 Biogen Idec Ma Inc. Stabilized Fc polypeptides with reduced effector function and methods of use
EP2432803A2 (en) 2009-05-20 2012-03-28 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
WO2010135534A2 (en) 2009-05-20 2010-11-25 Children's Medical Center Corporation Compositions for the treatment of metastatic cancer and methods of use thereof
JP5683581B2 (ja) 2009-06-30 2015-03-11 リサーチ ディベロップメント ファウンデーション 免疫グロブリンＦｃポリペプチド
CA2781519A1 (en) 2009-09-16 2011-03-24 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
KR101808602B1 (ko) 2009-10-07 2017-12-13 마크로제닉스, 인크. 푸코실화 정도의 변경으로 인해 개선된 이펙터 기능을 나타내는 Ｆｃ 영역-함유 폴리펩티드, 그것의 사용 방법
EP2504360B1 (en) 2009-11-23 2018-08-15 Amgen Inc. Monomeric antibody fc
GB0922209D0 (en) 2009-12-18 2010-02-03 Univ Nottingham Proteins, nucleic acid molecules and compositions
JP6200806B2 (ja) 2010-05-21 2017-09-20 メリマック ファーマシューティカルズ インコーポレーティッド 二重特異的融合タンパク質
WO2012006635A1 (en) 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Processable single chain molecules and polypeptides made using same
MX368531B (es) 2010-07-28 2019-10-07 Gliknik Inc Proteinas de fusion de fragmentos de proteinas humanas naturales para crear composiciones de fc de inmunoglobulinas multimerizadas ordenadamente.
US20130177555A1 (en) 2010-08-13 2013-07-11 Medimmune Limited Monomeric Polypeptides Comprising Variant FC Regions And Methods Of Use
RU2604490C2 (ru) 2010-11-05 2016-12-10 Займворкс Инк. ДИЗАЙН УСТОЙЧИВОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В Fc ДОМЕНЕ
CA2822366A1 (en) * 2010-12-23 2012-06-28 Janssen Biotech, Inc. Active protease-resistant antibody fc mutants
BR112013023653A2 (pt) 2011-03-17 2016-12-13 Univ Ramot anticorpo biespecífico, método de preparação do anticorpo, e composição farmacêutica
SG10201602371VA (en) 2011-03-25 2016-04-28 Glenmark Pharmaceuticals Sa Hetero-dimeric immunoglobulins
KR102052774B1 (ko) * 2011-11-04 2019-12-04 자임워크스 인코포레이티드 Ｆｃ 도메인 내의 돌연변이를 갖는 안정한 이종이합체 항체 설계
CA2875246A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Procoagulant compounds
WO2013192131A1 (en) * 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function
WO2014031646A2 (en) 2012-08-20 2014-02-27 Gliknik Inc. Molecules with antigen binding and polyvalent fc gamma receptor binding activity
CN110894231A (zh) 2012-10-17 2020-03-20 康诺贝林伦瑙有限公司 免疫调节蛋白
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
CN104558194B (zh) 2013-10-17 2018-04-27 泰州迈博太科药业有限公司 一类抗CD20-Flex双功能融合蛋白、其制备方法及用途
CN106029087A (zh) * 2013-12-20 2016-10-12 印第安纳大学研究及科技有限公司 脂质化肠降血糖素受体配体人免疫球蛋白fc区融合多肽
BR112016016416A2 (pt) 2014-01-15 2017-10-03 Hoffmann La Roche VARIANTES DE REGIÕES-"Fc" COM 'FcRn' MODIFICADAS E PROPRIEDADES DE LIGAÇÃO DE PROTEÍNA "A" MANTIDAS
CA2931979A1 (en) 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Fc-region variants with modified fcrn-binding properties
AU2015226101B2 (en) 2014-03-05 2019-08-22 Ucb Biopharma Sprl Multimeric Fc proteins
BR112016020368A2 (pt) 2014-03-05 2018-01-23 Ucb Biopharma Sprl proteínas fc multiméricas
AU2015248785A1 (en) 2014-04-16 2016-11-24 Ucb Biopharma Sprl Multimeric Fc proteins
CN106661125B (zh) 2014-05-02 2021-10-01 动量制药公司 涉及工程化Fc构建体的组合物和方法
NZ726520A (en) 2014-05-29 2018-12-21 Macrogenics Inc Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
US12391759B2 (en) 2016-03-02 2025-08-19 Momenta Pharmaceuticals, Inc. Methods related to engineered Fc constructs
KR102635635B1 (ko) 2016-05-23 2024-02-14 모멘타 파머슈티컬스 인코포레이티드 유전자 조작 Fc 작제물에 관한 조성물 및 방법
CN110650748B (zh) * 2017-01-06 2024-01-02 动量制药公司 与经工程改造的Fc构建体相关的组合物和方法

Also Published As

Publication number Publication date
IL263213B1 (en) 2024-01-01
EP3484514A1 (en) 2019-05-22
DK3484514T3 (da) 2024-01-29
KR102635635B1 (ko) 2024-02-14
AU2017272111B2 (en) 2024-05-16
JP7295301B2 (ja) 2023-06-20
JP2022095685A (ja) 2022-06-28
US20220049019A1 (en) 2022-02-17
JP7045333B2 (ja) 2022-03-31
IL309293A (en) 2024-02-01
KR102590061B1 (ko) 2023-10-18
US20190284305A1 (en) 2019-09-19
JP7045333B6 (ja) 2022-05-06
CN109789203B (zh) 2022-08-05
KR20190021255A (ko) 2019-03-05
US11155640B2 (en) 2021-10-26
PL3484514T3 (pl) 2024-04-29
KR20190026684A (ko) 2019-03-13
IL263211A (en) 2018-12-31
EP3464376A4 (en) 2020-03-18
SG10202011624SA (en) 2021-01-28
KR102462084B1 (ko) 2022-11-02
SG11201810465RA (en) 2018-12-28
JP2025026880A (ja) 2025-02-26
IL263213A (en) 2018-12-31
AU2017272109A1 (en) 2019-01-17
ES2973251T3 (es) 2024-06-19
US12297291B2 (en) 2025-05-13
CA3025310A1 (en) 2017-11-30
AU2017272109B2 (en) 2024-07-25
CN116063540A (zh) 2023-05-05
EP3464376A1 (en) 2019-04-10
AU2017272111A1 (en) 2019-01-17
JP2019519528A (ja) 2019-07-11
US20210221917A1 (en) 2021-07-22
IL263211B1 (en) 2023-05-01
IL263211B2 (en) 2023-09-01
US11623964B2 (en) 2023-04-11
EP3484514B1 (en) 2023-12-06
JP2022068176A (ja) 2022-05-09
WO2017205436A1 (en) 2017-11-30
CN109963869A (zh) 2019-07-02
BR112018074032A2 (pt) 2019-02-26
US20240067757A1 (en) 2024-02-29
IL263213B2 (en) 2024-05-01
WO2017205434A1 (en) 2017-11-30
CN118206639A (zh) 2024-06-18
JP2019519527A (ja) 2019-07-11
KR20220151025A (ko) 2022-11-11
CN109789203A (zh) 2019-05-21
SG11201810466PA (en) 2018-12-28
NZ749279A (en) 2025-08-29
EP3484514A4 (en) 2020-08-12
CA3025306A1 (en) 2017-11-30
NZ749292A (en) 2025-08-29

Similar Documents

Publication Publication Date Title
BR112018074056A2 (pt) composições e métodos relacionados a construtos de fc manipulados
BR112018008901A8 (pt) formulações subcutâneas de anticorpos anti-cd 38 e seus usos
CY1124131T1 (el) Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου
MX2022005202A (es) Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos.
EP4299595A3 (en) Compositions and methods related to engineered fc constructs
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
CO2020012347A2 (es) Anticuerpos anti-hla-g y usos de los mismos.
CY1125400T1 (el) Νεα αντι-ανθρωπινα αντισωματα gpvi και χρησεις αυτων
DK3411404T3 (da) Psma- og cd3-bispecifikke t-celleinddragende antistofkonstruktioner
PH12017500322A1 (en) Anti-her2 antibodies and immunoconjugates
LT3443009T (lt) Anti-tim-3 antikūnai ir kompozicijos
MX385585B (es) Anticuerpos anti-c10orf54 y usos de los mismos.
EA201791485A1 (ru) Анти-cd47-антитела и их применения
MX384364B (es) Anticuerpos anti-pd-l1 y sus usos de diagnóstico.
BR112017001796A2 (pt) composições de flagelina e seus usos
IL263764A (en) Anti-cd19 antibody formulations
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
BR112021011124A2 (pt) Anelossomos e métodos de uso
PH12020550930A1 (en) Human igg fc domain variants with improved effector function
BR112017009792A2 (pt) anticorpos anti-pdgf-b e métodos de uso
MX2017002469A (es) Composiciones de matrices extracelulares.
MX377774B (es) Formulaciones de proteinas.
BR112018009004A8 (pt) conjugados anti-cd3-folato e seus usos
EP3565588A4 (en) COMPOSITIONS AND METHODS RELATING TO MODIFIED FC CONSTRUCTIONS
MX382864B (es) Formulaciones de anticuerpos cristalinos.

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]